Medicines

Medtech sector seeks standard GST rate, export incentives in Budget

The scheme aims to refund to exporters the embedded central, state, and local duties and taxes paid on inputs that were so far not refunded or rebated

Clinical trials of medicines often done in poor countries, says SC

Observing clinical trials of medicines and vaccines were often carried out in poor countries, the Supreme Court on Wednesday allowed a petitioner to file submissions and objections to the rules framed by the Centre on the issue. A bench comprising Justices Hrishikesh Roy and S V N Bhatti considered the submissions of Centre's additional solicitor general Archana Pathak Dave who said rules for new drugs and clinical trials were framed in 2019. "We know that the clinical trials are conducted in poor countries," the bench said. Following the rules, Dave said New Drugs and Clinical Trials (Amendment) Rules were notified in 2024 to streamline the approval process for clinical trials and new drugs in India which aimed to improve patient safety protocols and ensure compliance with global standards. Senior advocate Sanjay Parikh, appearing for NGO Swasthya Adhikar Manch, which filed a PIL in 2012 alleging large-scale clinical drug trials across the country by multinational pharmaceutical .

Booster shot as Medicity set to come up in 200 acres area in Chhattisgarh

Under the project, health facilities with about 5,000 bed capacity would be developed via private investment

Akums announces new facility for lyophilized, sterile dosage manufacturing

Lyophilisation is the process of extracting water from drug particles at freezing temperatures, maintaining the drug's value and preserving the stability

Govt will curb manufacturing, sale of counterfeit medicines in UP: CM Yogi

The Uttar Pradesh government is committed to putting a stop on the manufacturing and sale of counterfeit medicines in the state, Chief Minister Yogi Adityanath said on Monday. Responding to a starred question raised by Samajwadi Party MLA Sachin Yadav during the Question Hour, the chief minister, in a written reply, said the government is taking stringent measures to curb this illicit trade. Yadav had asked whether the government intends to curb the manufacturing and sale of counterfeit medicines in the state and if details of actions taken against those involved would be presented before the House. The chief minister said the Food Safety and Drug Administration department has conducted a total of 24,492 enforcement actions, including 22,151 inspections and 2,341 raids. A total of 26,225 samples were collected, out of which 301 cases of counterfeit medicines were identified. Medicines valued at an estimated Rs 19.76 crore were seized, and legal cases were filed for 250 instances of

Flipkart's 10-minute medicine delivery to shake up online pharmacy market

Flipkart to launch 10-minute medicine delivery under its 'Flipkart Minutes' service, partnering with local chemists to tap into quick commerce and expand its online pharmacy footprint

Drug regulator CDSCO flags 3 drugs as spurious, 56 not of standard quality

CDSCO made the revelation in its monthly update for October; drugs include those used to treat acid reflux, lower cholesterol and reduce risk of heart disease

Alembic Pharmaceuticals gets USFDA nod for hypertension treatment capsules

Alembic Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic Diltiazem Hydrochloride extended-release capsules indicated for the treatment of hypertension. The approval by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Diltiazem Hydrochloride Extended-Release Capsules of strengths 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg, Alembic Pharmaceuticals Ltd (Alembic) said in a statement. These capsules are indicated for the treatment of hypertension. These capsules may be used alone or in combination with other antihypertensive medications. Moreover, Diltiazem Hydrochloride is also indicated for the management of chronic stable angina and angina due to coronary artery spasm, the company said. Diltiazem Hydrochloride extended-release capsules 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg have an estimated market size of USD 105.3 million for the 12 months ended June 2024, the company ...

Teva faces fine for disparaging rival multiple sclerosis medicine: Report

The EU competition enforcer's tough line underscores its concerns that such practices could stifle innovation in the pharmaceutical industry

Special medical stores to be opened in tehsils for AYUSH medicines: Jadhav

Union Minister Prataprao Jadhav on Monday said special medical stores will be opened in every tehsil of the country to ensure adequate availability of AYUSH medicines. The Union AYUSH Minister also said the government is mulling on ways to ensure Ayurvedic medicines based on traditional knowledge get due recognition. "The traditional knowledge of Ayurveda has been passed on from generation to generation. There are very good medicines in Ayurveda, but they have no recognition. We are wondering how these drugs can be recognised," he told PTI here. "Only a few AYUSH medicines are available in common medical stores, due to which patients and doctors prescribing these medicines face problems. The government wants to ensure AYUSH drugs come into the market in abundance after research. These medicines should be available everywhere. For this, we are trying to open at least one special medical store of AYUSH medicines in every tehsil of the country," he said. AYUSH hospitals are also being

Glenmark Pharma introduces generic eye treatment medication in US

Glenmark Pharmaceuticals on Monday said its US-based subsidiary has introduced a generic medication used for eye itching. Glenmark Therapeutics Inc, USA has launched Olopatadine Hydrochloride Ophthalmic Solution (OTC) in the US market, the Mumbai-based drug maker said in a regulatory filing. Fabio Moreno, Head of OTC Sales & Marketing, Glenmark Pharmaceuticals Inc, said the launch of Olopatadine Ophthalmic Solution (USP, 0.1 per cent), addresses a growing demand for a new supplier in this category. "This addition highlights our commitment to meeting market needs and providing high-quality over-the-counter solutions for our customers," Moreno said.

‘Allopathy medicines are poison’: Baba Ramdev lands into hot waters

Govt plans regulatory crackdown on similar-sounding, look-alike drug brands

Drug manufacturers in India will soon be required to upload their product formulations and brand names on the government's portal

Online pharmacy players look for regulatory framework for industry

A division bench of the Madras HC has set aside an earlier order that disallowed them to engage in digital sale of medicines

Govt planning regulatory crackdown on look-alike, sound-alike drug names

In order to safeguard patients, the Drug Technical Advisory Board (DTAB) proposed banning the production and marketing of distinct drugs under identical brand names

AstraZeneca aims to grow its total revenue by 75% to $80 bn by 2030

The Anglo-Swedish drugmaker had reported total revenue of $45.81 billion last year and earlier expected to launch at least 15 new medicines between 2023 and 2030

Doctors not mandated to inform patients on drug side effects: Delhi HC

Delhi High Court dismissed a public interest litigation that sought to enforce the compulsory disclosure of drug side effects by doctors to the patients

World Homeopathy Day 2024: All about Homoeopathy and its benefits

The target of homoeopathy is to address and to give therapy the whole of an individual, including their character, way of life, hereditary predispositions, and disease history

5 dead, over 100 hospitalised from recalled Japanese health supplements

Kobayashi Pharmaceutical Co. came under fire for not going public quickly with problems known internally as early as January

Misleading ads case: SC orders Ramdev, Balakrishna to appear in person

Patanjali Ayurved has faced scrutiny from the top court for disseminating misleading advertisements that claim to treat medical conditions, a violation of the Magic Remedies Act, 1954